Ampio Pharmaceuticals (OTCPK:AMPE) - Prezzo delle azioni, notizie e analisi

AMPE Panoramica delle azioni

Ampio Pharmaceuticals, Inc. è una società biofarmaceutica che si occupa dello sviluppo di terapie per il trattamento dell'osteoartrite del ginocchio (OAK) negli Stati Uniti. Maggiori dettagli

AMPE analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli utili sono diminuiti del 28.4% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( $85K )

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

+ 2 più rischi

Ampio Pharmaceuticals, Inc. Concorrenti

Veritas Farms

OTCPK:VFRM

US$81.9k

CBD Life Sciences

OTCPK:CBDL

US$1.4m

Hero Technologies

OTCPK:HENC

US$563.0

Kid Castle Educational

OTCPK:KDCE

US$357.2k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Ampio Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.0026
Massimo di 52 settimane	US$7.47
Minimo di 52 settimane	US$0.000001
Beta	3.71
1Variazione di 1 mese	18.18%
Variazione a 3 mesi	18.18%
Variazione di 1 anno	-99.87%
3Variazione a 3 anni	-100.00%
Variazione a 5 anni	-100.00%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Feb 17

Rendimenti per gli azionisti

	AMPE	US Pharmaceuticals	US Mercato
7D	-74.0%	3.4%	1.6%
1Y	-99.9%	14.2%	32.3%

Ritorno vs Industria: AMPE ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 14.2 % nell'ultimo anno.

Rendimento vs Mercato: AMPE ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.3 % nell'ultimo anno.

Volatilità dei prezzi

Is AMPE's price volatile compared to industry and market?
AMPE volatility
AMPE Average Weekly Movement	324.1%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di AMPE è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di AMPE è diminuita da 1564% a 324% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	6	Mike Martino	ampiopharma.com

Ampio Pharmaceuticals, Inc. è una società biofarmaceutica che si occupa dello sviluppo di terapie per il trattamento dell'osteoartrite del ginocchio (OAK) negli Stati Uniti. L'azienda sviluppa OA-201, una formulazione di piccole molecole per il trattamento del dolore da OAK. Ampio Pharmaceuticals, Inc. ha sede a Englewood, Colorado.

Ampio Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Ampio Pharmaceuticals con la sua capitalizzazione di mercato?
AMPE statistiche fondamentali
Capitalizzazione di mercato	US$85.27k
Guadagni(TTM)	-US$8.63m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

0.0x

Rapporto P/E

AMPE è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AMPE Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$8.63m
Guadagni	-US$8.63m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-7.60
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	5.3%

Come si è comportato AMPE nel lungo periodo?

Vedi performance storica e confronto

AMPE Panoramica delle azioni

Analisi del rischio

Ampio Pharmaceuticals, Inc. Concorrenti

OTCPK:VFRM

US$81.9k

OTCPK:CBDL

US$1.4m

OTCPK:HENC

US$563.0

OTCPK:KDCE

US$357.2k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased to US$3.50

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Chief Operating Officer exercised options and sold US$111k worth of stock

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

CFO, Corporate Secretary & Treasurer exercised options and sold US$56k worth of stock

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

CFO, Corporate Secretary & Treasurer exercised options to buy US$59k worth of stock.

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

New 90-day high: US$2.76

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: US$1.17

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - US$0.80

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Ampio Pharmaceuticals, Inc. Riepilogo dei fondamenti

0.0x

0.0x

Guadagni e ricavi